Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Aclaris Therapeutics in a note issued to investors on Thursday, February 27th. Leerink Partnrs analyst T. Smith expects that the biotechnology company will post earnings per share of ($0.13) for the quarter. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Aclaris Therapeutics' current full-year earnings is ($0.82) per share. Leerink Partnrs also issued estimates for Aclaris Therapeutics' Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.15) EPS and Q4 2025 earnings at ($0.16) EPS.
A number of other research firms also recently weighed in on ACRS. BTIG Research upgraded Aclaris Therapeutics from a "neutral" rating to a "buy" rating and set a $8.00 price target on the stock in a research report on Tuesday, November 19th. HC Wainwright upgraded Aclaris Therapeutics from a "neutral" rating to a "buy" rating and set a $20.00 price objective on the stock in a report on Monday, December 23rd. Leerink Partners upgraded Aclaris Therapeutics from a "market perform" rating to an "outperform" rating and lifted their price objective for the stock from $2.00 to $7.00 in a report on Tuesday, November 19th. Piper Sandler upgraded Aclaris Therapeutics from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $3.00 to $13.00 in a report on Monday, November 18th. Finally, Jefferies Financial Group upgraded Aclaris Therapeutics from a "hold" rating to a "buy" rating and boosted their price target for the company from $2.00 to $7.00 in a report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $11.00.
Get Our Latest Stock Analysis on Aclaris Therapeutics
Aclaris Therapeutics Price Performance
NASDAQ ACRS traded down $0.03 during trading hours on Monday, reaching $1.82. 680,253 shares of the stock traded hands, compared to its average volume of 758,715. The stock has a 50 day simple moving average of $2.36 and a two-hundred day simple moving average of $2.17. Aclaris Therapeutics has a 1 year low of $0.95 and a 1 year high of $5.17. The company has a market cap of $130.00 million, a price-to-earnings ratio of -3.50 and a beta of 0.50.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. Assenagon Asset Management S.A. boosted its position in Aclaris Therapeutics by 113.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 397,362 shares of the biotechnology company's stock valued at $985,000 after acquiring an additional 211,585 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in Aclaris Therapeutics by 187.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company's stock valued at $382,000 after acquiring an additional 216,826 shares in the last quarter. BML Capital Management LLC boosted its position in Aclaris Therapeutics by 9.7% during the 3rd quarter. BML Capital Management LLC now owns 14,250,000 shares of the biotechnology company's stock valued at $16,388,000 after acquiring an additional 1,261,866 shares in the last quarter. Geode Capital Management LLC boosted its position in Aclaris Therapeutics by 9.3% during the 3rd quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company's stock valued at $974,000 after acquiring an additional 72,309 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Aclaris Therapeutics during the 3rd quarter valued at approximately $1,053,000. Hedge funds and other institutional investors own 98.34% of the company's stock.
About Aclaris Therapeutics
(
Get Free Report)
Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
Featured Articles
Before you consider Aclaris Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aclaris Therapeutics wasn't on the list.
While Aclaris Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
